"On behalf of the entire management team and Board, I would like to thank Warren for his considerable contribution and wish him well in his future endeavours," said James R. Howard-Tripp, President and Chief Executive Officer of Labopharm Inc. "Mark's extensive international and public company expertise will play an important role as we continue to pursue the global commercialization of our once-daily formulation of tramadol and the further development of our pipeline and we welcome him to the team."
Mr. D'Souza has held a number of progressively senior financial management positions, most recently as Vice President, Finance with Quebecor Media Inc. In addition to several international positions with the Quebecor group of companies, he has served as Finance Director of the Societe Generale de Financement du Quebec and held corporate finance positions at the Royal Bank of Canada and the Union Bank of Switzerland (Canada). Mr. D'Souza is a member of the Quebec bar and began his career with Hemens Harris and Associatesas a Lawyer. He holds an MBA from the Ecole des Hautes Etudes Commerciales and an LLL from the University of Montreal.
About Labopharm Inc.
Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) is an international, specialty pharmaceutical company focused on the development of drugs incorporating the Company's proprietary advanced controlled-release technologies. Labopharm's lead in-house product, a once-daily formulation of the analgesic tramadol, has received regulatory approval in 22 European countries and Mexico and commercial launch of the product by licensed distributors across Europe is underway. In the U.S., the Company's NDA for once-daily tramadol is under review at the FDA and the Company has secured a licensing and distribution agreement with Purdue Pharma. The Company's pipeline includes a combination of in-house and partnered programs with products both in clinical trials and in preclinical development. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of clinical studies, the uncertainties related to the regulatory process and the commercialization of the drug thereafter. Investors should consult the Corporation's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
Source: Labopharm Inc.
